2015
DOI: 10.1016/j.atherosclerosis.2015.07.020
|View full text |Cite
|
Sign up to set email alerts
|

Cascade screening of familial hypercholesterolemia must go on

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(12 citation statements)
references
References 14 publications
0
12
0
Order By: Relevance
“…Some studies with other populations have shown the importance of performing screenings to identify a family history of dyslipidemia in children. 23 , 24 , 25 It is known that familial hypercholesterolemia is a common genetic cause of premature coronary disease and is an autosomal dominant disorder present even in individuals with a healthy lifestyle. A diagnosis of familial hypercholesterolemia is based on phenotypic criteria, involving high serum concentrations of LDL-c, plus a family history of elevated LDL-c, premature coronary disease and/or genetic diagnoses.…”
Section: Discussionmentioning
confidence: 99%
“…Some studies with other populations have shown the importance of performing screenings to identify a family history of dyslipidemia in children. 23 , 24 , 25 It is known that familial hypercholesterolemia is a common genetic cause of premature coronary disease and is an autosomal dominant disorder present even in individuals with a healthy lifestyle. A diagnosis of familial hypercholesterolemia is based on phenotypic criteria, involving high serum concentrations of LDL-c, plus a family history of elevated LDL-c, premature coronary disease and/or genetic diagnoses.…”
Section: Discussionmentioning
confidence: 99%
“…The Netherlands: Data was collected from all consecutive children with FH who visited the outpatient lipid clinics of the Erasmus MC or Sophia Children Hospital The Netherlands for the first time under 18 years old, between April 1993 and February 2018 and was entered in a database. The diagnosis of FH was based either on identification of a FH pathogenic variant in LDLR//APOB/PCSK9 or Dutch Lipid Clinic Network criteria with definite FH score ≥8 [25,27]. Children with homozygous FH were excluded.…”
Section: Country-specific Patient Identificationmentioning
confidence: 99%
“…In 2017 we obtained funding from the International Atherosclerosis Society (IAS) to collect similar data from seven other European countries, to establish an International Paediatric FH Register and to compare across Europe the characteristics at diagnosis, including the proportion with an identified mutation and the proportion of children with LDL-C < 4.0 mmol/l, and the age of initiation and lipid-lowering effect of statin treatment in the different countries. Although information on children in the UK [22], Portugal [24], The Netherlands [25] and Norway [26] cohorts has been published previously, the novelty of this present study is the analysis of the between-country similarities and differences in diagnostic and treatment strategies currently being used.…”
Section: Introductionmentioning
confidence: 99%
“…There are currently no systematic efforts to apply cascade screening for Tier 1 genetic conditions among the general population in Europe apart from the Netherlands, which successfully implemented a cascade screening program for FH. The implementation of this pioneering public health program helped identify more than 28,000 asymptomatic cases [ 55 ] and provides proof-of-concept that cascade screening can be applied in other settings [ 56 ].…”
Section: Introductionmentioning
confidence: 99%